

CITATION REPORT

List of articles citing

Effects of hydroxychloroquine treatment on QT interval

DOI: 10.1016/j.hrthm.2020.06.029
Heart Rhythm, 2020, 17, 1930-1935.

Source: <https://exaly.com/paper-pdf/77096366/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
40	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106212	14.3	9
39	Response to: 'Correspondence on ': hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef ' by Lo. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
38	Prolonged QT Interval in SARS-CoV-2 Infection: Prevalence and Prognosis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	15
37	Hydroxychloroquine-Induced Premature Ventricular Contractions in a Patient With COVID-19 Disease. <i>Annals of Pharmacotherapy</i> , 2021 , 55, 1061-1062	2.9	0
36	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. <i>New Microbes and New Infections</i> , 2020 , 37, 100747	4.1	11
35	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia. <i>International Journal of Infectious Diseases</i> , 2021 , 102, 110-114	10.5	3
34	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 17-27	2.2	14
33	Hydroxychloroquine: Not a Heart Breaker!. <i>Arthritis Care and Research</i> , 2021 , 73, 770-771	4.7	
32	Patients with rheumatoid arthritis exposed to COVID-19: A family cluster report. <i>Modern Rheumatology</i> , 2021 , 31, 514-517	3.3	
31	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. <i>Rheumatology International</i> , 2021 , 41, 257-273	3.6	0
30	Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes. <i>Toxicological Sciences</i> , 2021 , 180, 356-368	4.4	7
29	Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience. <i>Journal of Nephrology</i> , 2021 , 1	4.8	4
28	QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine. <i>Modern Rheumatology</i> , 2021 , 31, 1107-1112	3.3	3
27	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101658	5.3	2
26	COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 377, 265-272	4.7	7
25	Implantable Cardioverter-Defibrillator Shocks During COVID-19 Outbreak. <i>Journal of the American Heart Association</i> , 2021 , 10, e019708	6	2
24	Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. <i>Scientific Reports</i> , 2021 , 11, 12414	4.9	6

23	Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy. <i>Medicine (United States)</i> , 2021 , 100, e26538	1.8	2
22	Mécanismes possiblement impliqués dans les effets antiviraux de la chloroquine et de l'hydroxychloroquine. Quelle réalité pour le traitement de la COVID-19?. <i>Toxicologie Analytique Et Clinique</i> , 2021 , 33, 237-237	0.4	
21	Few Adverse Cardiovascular Events Among Patients With Rheumatoid Arthritis Receiving Hydroxychloroquine: Are We Reassured?. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1571-1573	9.5	0
20	Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
19	COVID-19 related pressure injuries in patients and personnel: A systematic review. <i>Journal of Tissue Viability</i> , 2021 , 30, 283-290	3.2	5
18	Electrophysiological and Proarrhythmic Effects of Hydroxychloroquine Challenge in Guinea-Pig Hearts. <i>ACS Pharmacology and Translational Science</i> , 2021 , 4, 1639-1653	5.9	0
17	The Impact of Deranged Glucose Metabolism and Diabetes in The Pathogenesis and Prognosis of The Novel Sars-Cov-2: A Systematic Review of Literature. <i>Current Diabetes Reviews</i> , 2021 ,	2.7	
16	Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 724-730	2.2	8
15	American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2151-2160	9.5	2
14	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for Covid-19 Outpatients in Saudi Arabia.		
13	Glycemic efficacy and safety of hydroxychloroquine in type 2 diabetes mellitus: A systematic review and meta-analysis of relevance amid the COVID-19 pandemic. <i>International Journal of Noncommunicable Diseases</i> , 2020 , 5, 184	0.6	0
12	Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. <i>Inflammopharmacology</i> , 2021 , 29, 1795-1805	5.1	
11	Predictors of QT Interval Prolongation in Critically-ill Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine.		
10	Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.. <i>BMJ Open</i> , 2022 , 12, e051579	3	1
9	COVID-19 Cardiovascular Connection: A Review of Cardiac Manifestations in COVID-19 Infection and Treatment Modalities.. <i>Current Problems in Cardiology</i> , 2022 , 101186	17.1	1
8	Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation.. <i>Drugs in R and D</i> , 2022 ,	3.4	0
7	Increase in Ca ²⁺ -Activated cAMP/PKA Signaling Prevents Hydroxychloroquine-Induced Bradycardia of the Cardiac Pacemaker. <i>Frontiers in Physiology</i> , 2022 , 13,	4.6	1
6	Hydroxychloroquine. <i>Journal of the American College of Cardiology</i> , 2022 , 80, 47-49	15.1	

- 5 Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine—possible prevention strategy for COVID-19?. ○
- 4 Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. ○
- 3 Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. **2022**, 14, 2551 ○
- 2 Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial. **2023**, 16, ○
- 1 A Review of Pathology and Analysis of Approaches to Easing Kidney Disease Impact: Host-Pathogen Communication and Biomedical Visualization Perspective. **2023**, 41-57 ○